Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis Journal Article


Authors: Bristow, R. E.; Puri, I.; Chi, D. S.
Article Title: Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis
Abstract: Objective: To determine the relative effect of multiple prognostic variables on overall post-recurrence survival time among cohorts of patients with recurrent ovarian cancer undergoing cytoreductive surgery. Methods: Forty cohorts of patients with recurrent ovarian cancer (2019 patients) meeting study inclusion criteria were identified from the MEDLINE database (1983-2007). Simple and multiple linear regression analyses, with weighted correlation calculations, were used to assess the effect on median post-recurrence survival time of the following variables: year of publication, age, disease-free interval, localized disease, tumor grade and histology, the proportion of patients undergoing complete cytoreductive surgery, requirement for bowel resection, and the sequence of cytoreductive surgery and salvage chemotherapy. Results: The mean weighted median disease-free interval prior to cytoreductive surgery was 20.2 months, and the mean weighted median overall post-recurrence survival time was 30.3 months. The weighted mean proportion of patients in each cohort undergoing complete cytoreductive surgery was 52.2%. Median survival improved with increasing year of publication (p = 0.009); however, the only statistically significant clinical variable independently associated with post-recurrence survival time was the proportion of patients undergoing complete cytoreductive surgery (p = 0.019). After controlling for all other factors, each 10% increase in the proportion of patients undergoing complete cytoreductive surgery was associated with a 3.0 month increase in median cohort survival time. Conclusions: Among patients undergoing operative intervention for recurrent ovarian cancer, the proportion of patients undergoing complete cytoreductive surgery is independently associated with overall post-recurrence survival time. For this select group of patients, the surgical objective should be resection of all macroscopic disease. © 2008 Elsevier Inc. All rights reserved.
Keywords: cancer chemotherapy; cancer survival; review; cisplatin; doxorubicin; fluorouracil; gemcitabine; paclitaxel; cancer radiotherapy; topotecan; recurrent cancer; cancer grading; ovarian cancer; cytoreductive surgery; ovarian neoplasms; ovary cancer; neoplasm recurrence, local; etoposide; recurrence; cyclophosphamide; melphalan; vincristine; histology; ifosfamide; age; docetaxel; survival time; correlation analysis; medline; altretamine; epirubicin; mitomycin c; platinum; vindesine; disease free interval; intestine resection; multiple linear regression analysis; gynecologic surgical procedures
Journal Title: Gynecologic Oncology
Volume: 112
Issue: 1
ISSN: 0090-8258
Publisher: Elsevier Inc.  
Date Published: 2009-01-01
Start Page: 265
End Page: 274
Language: English
DOI: 10.1016/j.ygyno.2008.08.033
PUBMED: 18937969
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 31" - "Export Date: 30 November 2010" - "CODEN: GYNOA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Dennis S Chi
    707 Chi